Androgens and Anabolic Steroids (AAS) Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Androgens and Anabolic Steroids (AAS) Market Report is Segmented by Product Type (Testosterone, Methyltestosterone, Oxandrolone, and Other Anabolic Steroids), Application (Hypogonadism, Anemia, Breast Cancer, and Other Applications), Route of Administration (Oral, Injectable and Other Route of Administration), End-User (Hospitals, Specialty Clinics, Homecare Settings and Other End Users), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Report Offers the Value in USD for the Above Segments.

Androgens and Anabolic Steroids (AAS) Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Androgens And Anabolic Steroids Market Size

Androgens And Anabolic Steroids Market Summary
Study Period 2021 - 2030
Market Size (2025) USD 78.46 Billion
Market Size (2030) USD 131.62 Billion
CAGR (2025 - 2030) 10.90 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Androgens And Anabolic Steroids Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Androgens And Anabolic Steroids Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Androgens and Anabolic Steroids Market Analysis

The Androgens And Anabolic Steroids Market size is estimated at USD 78.46 billion in 2025, and is expected to reach USD 131.62 billion by 2030, at a CAGR of 10.9% during the forecast period (2025-2030).

Various factors, such as the increase in the prevalence of medical conditions, the high adoption of anabolic steroids in sports and bodybuilding, and technological advancements in androgens and anabolic steroids, will lead to market growth during the forecast period.

The growing prevalence of conditions such as hypogonadism (low testosterone levels) and delayed puberty in men is driving the need for androgen replacement therapy. For instance, an article published in the International Journal of Endocrinology in February 2023 mentioned that the worldwide prevalence of male hypogonadism (MH) ranges from 6% to 12%, depending on the specific study population. Additionally, anabolic steroids are also utilized in treating conditions that lead to muscle wasting, including cancer and other various chronic diseases. For instance, according to the data updated by the Global Observatory Council (GLOBOCON) in February 2024, reported that the incidence of breast cancer is expected to rise from 2.3 million cases in 2022 to 2.7 million in 2030. Thus, the increasing number of breast cancer patients are anticipated to utilize anabolic steroids for the treatment of estrogen receptor-positive breast cancer with the reduction of estrogen levels, which, in turn, is expected to boost market growth.

Additionally, market players incorporate strategies to introduce technologically advanced drug delivery systems, including long-acting injectables and topical treatments, which have simplified androgen therapies for patients, driving the market growth. For instance, in November 2023, Astellas Pharma Inc. entered into an agreement to acquire Propella Therapeutics, Inc. Through this acquisition, Astellas gained access to PRL-02 (abiraterone decanoate), an advanced androgen biosynthesis inhibitor under development by Propella for prostate cancer treatment. PRL-02 is an innovative, long-acting prodrug of abiraterone, which may offer enhanced efficacy and safety compared to current treatment alternatives due to its high selectivity in inhibiting CYP17 lyase. Moreover, according to the data published by the Hair Science Organization in June 2023, mentioned that GT20029 is an innovative topical androgen receptor degrader medication developed by Kintor Pharmaceutical Ltd. to address pattern hair loss (androgenetic alopecia) and acne vulgaris. The drug has successfully completed phase I clinical trials involving both men and women in China and the United States, and phase II clinical trials have started. Thus, such market player initiatives to introduce innovative products are anticipated to drive their usage, thereby boosting the market growth.

Hence, the increase in the prevalence of medical conditions such as hypogonadism and breast cancer among patients and market player strategies to introduce technologically advanced androgen and anabolic steroids are the significant factors driving the market growth. However, the regulatory and legal restrictions, as well as side effects and health risks, may affect the market growth of androgens and anabolic steroids over the forecast period.

Androgens and Anabolic Steroids Industry Overview

The androgens and anabolic steroids market is moderately fragmented because large and mid-sized companies contribute to the market share. The market players are adopting various approaches, including mergers and acquisitions, partnerships, and new product launches. Some of the prominent players are Pfizer Inc., Abbvie Inc., Endo Pharmaceuticals Inc., Teva Pharmaceuticals, and Cipla Limited, among others. 

Androgens and Anabolic Steroids Market Leaders

  1. Pfizer Inc.

  2. Abbvie Inc.

  3. Endo Pharmaceuticals Inc.

  4. Teva Pharmaceuticals

  5. Cipla Limited

  6. *Disclaimer: Major Players sorted in no particular order
Androgens and Anabolic Steroids Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Androgens and Anabolic Steroids Market News

  • June 2024: Mangoceuticals, Inc. introduced its proprietary formulations of Enclomiphene Citrate, Pregnenolone, and Dehydroepiandrosterone (DHEA) in an oral dissolvable tablet (ODT) in the United States. These formulations help restore hormonal balance and naturally elevate testosterone levels in men.
  • February 2024: Lipocine Inc. introduced that the commercialization of TLANDO in the United States was handed over to its licensee, Verity Pharma. This transition ensures that patients continue to have access to TLANDO, an oral testosterone replacement therapy (TRT) option approved by the United States Food and Drug Administration (FDA) that eliminates the need for dose titration.

Androgens and Anabolic Steroids Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Prevalence of Medical Conditions
    • 4.2.2 High Adoption of Anabolic Steroids in Sports and Bodybuilding
    • 4.2.3 Technological Advancements in Androgens and Anabolic Steroids
  • 4.3 Market Restraints
    • 4.3.1 Regulatory and Legal Restrictions
    • 4.3.2 Side Effects and Health Risks
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product Type
    • 5.1.1 Testosterone
    • 5.1.2 Methyltestosterone
    • 5.1.3 Oxandrolone
    • 5.1.4 Other Anabolic Steroids (Nandrolone, Stanozolol and others)
  • 5.2 By Application
    • 5.2.1 Hypogonadism
    • 5.2.2 Anemia
    • 5.2.3 Breast Cancer
    • 5.2.4 Other Applications (Muscle Wasting Diseases, Delayed Puberty and others)
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Injectable
    • 5.3.3 Other Route of Administration (Topical, Transdermal and others)
  • 5.4 By End-User
    • 5.4.1 Hospitals
    • 5.4.2 Specialty Clinics
    • 5.4.3 Homecare Settings
    • 5.4.4 Other End User (Fitness Centers and Gyms)
  • 5.5 By Distribution Channel
    • 5.5.1 Hospital Pharmacy
    • 5.5.2 Retail Pharmacy
    • 5.5.3 Online Pharmacy
  • 5.6 Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
    • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc.
    • 6.1.2 Abbvie Inc.
    • 6.1.3 Bayer AG
    • 6.1.4 Endo Pharmaceuticals Inc.
    • 6.1.5 Teva Pharmaceuticals
    • 6.1.6 Viatris Inc.
    • 6.1.7 Sun Pharmaceutical Industries Ltd.
    • 6.1.8 Cipla Limited
    • 6.1.9 Anatares Pharma Inc.
    • 6.1.10 Perrigo Company plc
    • 6.1.11 Aurobindo Pharma
    • 6.1.12 Zydus Cadila
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Androgens and Anabolic Steroids Industry Segmentation

According to the scope, androgens are natural hormones crucial for male development and reproduction. In contrast, anabolic steroids are synthetic substances developed to replicate these effects, primarily focusing on muscle growth and tissue repair. These steroids are utilized to address delayed puberty in adolescent males, breast cancer in females, and conditions like hypogonadism and impotence in males. Additionally, they treat anemia, osteoporosis, weight loss, and various other disorders related to hormonal imbalances.

The androgens and anabolic steroids market is segmented by product type, application, route of administration, end-user, distribution channel, and geography. By product type, the market is segmented into testosterone, methyltestosterone, oxandrolone, and other anabolic steroids. By application, the market is segmented into hypogonadism, anemia, breast cancer, and other applications. By route of administration, the market is segmented into oral, injectable, and other routes of administration. By end-user, the market is segmented into hospitals, specialty clinics, homecare settings and other end users. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.

By Product Type Testosterone
Methyltestosterone
Oxandrolone
Other Anabolic Steroids (Nandrolone, Stanozolol and others)
By Application Hypogonadism
Anemia
Breast Cancer
Other Applications (Muscle Wasting Diseases, Delayed Puberty and others)
By Route of Administration Oral
Injectable
Other Route of Administration (Topical, Transdermal and others)
By End-User Hospitals
Specialty Clinics
Homecare Settings
Other End User (Fitness Centers and Gyms)
By Distribution Channel Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Androgens and Anabolic Steroids Market Research FAQs

How big is the Androgens And Anabolic Steroids Market?

The Androgens And Anabolic Steroids Market size is expected to reach USD 78.46 billion in 2025 and grow at a CAGR of 10.90% to reach USD 131.62 billion by 2030.

What is the current Androgens And Anabolic Steroids Market size?

In 2025, the Androgens And Anabolic Steroids Market size is expected to reach USD 78.46 billion.

Who are the key players in Androgens And Anabolic Steroids Market?

Pfizer Inc., Abbvie Inc., Endo Pharmaceuticals Inc., Teva Pharmaceuticals and Cipla Limited are the major companies operating in the Androgens And Anabolic Steroids Market.

Which is the fastest growing region in Androgens And Anabolic Steroids Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Androgens And Anabolic Steroids Market?

In 2025, the North America accounts for the largest market share in Androgens And Anabolic Steroids Market.

What years does this Androgens And Anabolic Steroids Market cover, and what was the market size in 2024?

In 2024, the Androgens And Anabolic Steroids Market size was estimated at USD 69.91 billion. The report covers the Androgens And Anabolic Steroids Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Androgens And Anabolic Steroids Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Androgens and Anabolic Steroids Industry Report

Statistics for the 2025 Androgens And Anabolic Steroids market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Androgens And Anabolic Steroids analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Androgens and Anabolic Steroids Market Report Snapshots